
Initial assessment
GIP/GLP-1 agonist ineligible e.g. contraindicated bloods unsatisfactory, medication interaction etc
Patient declines GIP/GLP-1 agonist treatment **OR** wraparound care
SNOMED CODE: Referral to National Health Service obesity medication wraparound support pathway (procedure). SCTID: 2386201000000107
Note, both SNOMED codes required
Patient eligible for medical therapy and commences prescription medicine **AND** wraparound care
SNOMED CODE: Unsuitable for National Health Service obesity medication pathway (finding). SCTID: 2386221000000103
SNOMED CODE: National Health Service obesity medication pathway declined (situation). SCTID: 2386241000000105
SNOMED CODE: National Health Service obesity medication pathway started (situation). SCTID: 2386231000000101
End
Signpost to most appropriate alternative weight management service
End
SNOMED CODE: Obesity medication review SCTID: 2386251000000108
Obesity medication review appointment
Wraparound care completed after 9 months and patient continues on medication. Information obtained through wraparound care provider
SNOMED CODE: National Health Service obesity medication wraparound support pathway completed (situation) SCTID: 2386261000000106
Adverse reaction to medication*
Obesity medication stopped e.g. adverse reaction, intolerance, patient preference etc
Obesity medication pathway continues, continue to review as clinically appropriate. No SNOMED code to capture this.
SNOMED CODE: Adverse reaction to tirzepatide (disorder) SCTID: 2385981000000100
SNOMED CODE: Obesity medication stopped SCTID: 914821000000103
End
*Note if in a healthcare setting where semaglutide (Wegovy) is an option for management of obesity. SNOMED CODE: Adverse reaction to semaglutide (disorder) SCTID: 2385991000000103